Impact of vaccination with Cervarix™ on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age

Gynecologic Oncology

Volumn 110, Issue 3 SUPPL.1, 2008, Pages

  Harper, Diane M ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH COLLEGE   (United States)

Author keywords

Adolescents; Cervarix ; Cervical intraepithelial neoplasia (CIN); HPV vaccine; HPV 16 and 18; Vaccine efficacy

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; AS04 ADJUVANT; PHOSPHORYL LIPID A; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VERRUCA VULGARIS;

ADOLESCENT; ADULT; CANCER VACCINES; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 49549105596     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.06.029     Document Type: Article

References (32)

1. Muñoz N., Bosch F.X., de Sanjosé S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348 6 (2003) 518-527
2. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 121 3 (2007) 621-632
3. Clifford G., Franceschi S., Diaz M., Muñoz N., and Villa L.L. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24 Suppl 3 (2006) S26-S34
4. Dalstein V., Riethmuller D., Pretet J.L., Le Bail C.K., Sautiere J.L., Carbillet J.P., et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int. J. Cancer 106 3 (2003) 396-403
5. Kjaer S.K., van den Brule A.J., Paull G., Svare E.I., Sherman M.E., Thomsen B.L., et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 325 7364 (2002) 572-575
6. Liaw K.L., Glass A.G., Manos M.M., Greer C.E., Scott D.R., Sherman M., et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J. Natl. Cancer Inst. 91 11 (1999) 954-960
7. Nobbenhuis M.A., Walboomers J.M., Helmerhorst T.J., Rozendaal L., Remmink A.J., Risse E.K., et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 354 9172 (1999) 20-25
8. Schiffman M., and Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch. Pathol. Lab. Med. 127 8 (2003) 946-949
9. Schlecht N.F., Kulaga S., Robitaille J., Ferreira S., Santos M., Miyamura R.A., et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286 24 (2001) 3106-3114
10. Wallin K.L., Wiklund F., Angstrom T., Bergman F., Stendahl U., Wadell G., et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N. Engl. J. Med. 341 22 (1999) 1633-1638
11. Ylitalo N., Josefsson A., Melbye M., Sorensen P., Frisch M., Andersen P.K., et al. A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res. 60 21 (2000) 6027-6032
12. Woodman C.B., Collins S., Winter H., Bailey A., Ellis J., Prior P., et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 357 9271 (2001) 1831-1836
13. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl. Cancer Inst. 97 14 (2005) 1072-1079
14. Winer R.L., Kiviat N.B., Hughes J.P., Adam D.E., Lee S.K., Kuypers J.M., et al. Development and duration of human papillomavirus lesions, after initial infection. J. Infect. Dis. 191 5 (2005) 731-738
15. Schiffman M., Herrero R., Desalle R., Hildesheim A., Wacholder S., Rodriguez A.C., et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337 1 (2005) 76-84
16. Pagliusi S.R., and Teresa A.M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 23 5 (2004) 569-578
17. French K.M., Barnabas R.V., Lehtinen M., Kontula O., Pukkala E., Dillner J., et al. Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br. J. Cancer 96 3 (2007) 514-518
18. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 9447 (2004) 1757-1765
19. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 9518 (2006) 1247-1255
20. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 9580 (2007) 2161-2170
21. Gall S, Teixeira J, Wheeler C, Naud P, Harper D, Franco E, et al. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine. American Association for Cancer Research Annual Meeting, Los Angeles, CA, USA, Apr 14-18; 2007.
22. Castellsague X., Diaz M., de Sanjosé S., Muñoz N., Herrero R., Franceschi S., et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J. Natl. Cancer Inst. 98 5 (2006) 303-315
23. Erzen M., Mozina A., Bertole J., and Syrjänen K. Factors predicting disease outcome in early stage adenocarcinoma of the uterine cervix. Eur. J. Obstet. Gynecol. Reprod. Biol. 101 2 (2002) 185-191
24. Bulk S., Visser O., Rozendaal L., Verheijen R.H., and Meijer C.J. Cervical cancer in the Netherlands 1989-1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int. J. Cancer 113 6 (2005) 1005-1009
25. Smith H.O., Tiffany M.F., Qualls C.R., and Key C.R. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24-year population-based study. Gynecol. Oncol. 78 2 (2000) 97-105
26. Tjalma W.A., Van Waes T.R., Van den Eeden L.E., and Bogers J.J. Role of human papillomavirus in the carcinogenesis of squamous cell carcinoma and adenocarcinoma of the cervix. Best Pract. Res. Clin. Obstet. Gynaecol. 19 4 (2005) 469-483
27. Umezaki K., Sanezumi M., Okada H., Okamura A., Tsubra A., and Kanazaki H. Distribution of epithelial-specific antigen in uterine cervix with endocervical glandular dysplasia. Gynecol. Oncol. 66 3 (1997) 393-398
28. Vizcaino A.P., Moreno V., Bosch F.X., Muñoz N., Barros-Dios X.M., Borras J., et al. International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int. J. Cancer 86 3 (2000) 429-435
29. Vizcaino A.P., Moreno V., Bosch F.X., Muñoz N., Barros-Dios X.M., and Parkin D.M. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int. J. Cancer 75 4 (1998) 536-545
30. Cambruzzi E., Zettler C.G., and Alexandre C.O. Expression of Ki-67 and squamous intraepithelial lesions are related with HPV in endocervical adenocarcinoma. Pathol. Oncol. Res. 11 2 (2005) 114-120
31. Kyrgiou M., Koliopoulos G., Martin-Hirsch P., Arbyn M., Prendiville W., and Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 367 9509 (2006) 489-498
32. Goldie S.J., Kohli M., Grima D., Weinstein M.C., Wright T.C., Bosch F.X., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J. Natl. Cancer Inst. 96 8 (2004) 604-615